

Nicholas Pavlidis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3446885/publications.pdf>

Version: 2024-02-01

183
papers

8,891
citations

41627

51
h-index

56606

87
g-index

190
all docs

190
docs citations

190
times ranked

9958
citing authors

#	ARTICLE	IF	CITATIONS
1	ESO-ESSO-ESTRO Multidisciplinary Course in Oncology for Medical Students: 4 Years of Experience (2016â€“2019). Journal of Cancer Education, 2022, 37, 1239-1244.	0.6	7
2	ESO's career development program (2002-2021): Presentation and evaluation. Critical Reviews in Oncology/Hematology, 2022, 169, 103576.	2.0	0
3	Systematic review of the CUP trials characteristics and perspectives for next-generation studies. Cancer Treatment Reviews, 2022, 107, 102407.	3.4	13
4	Changing the landscape of European School of Oncologyâ€™European Society for Medical Oncology masterclasses in clinical oncology during the COVID-19 pandemic. Future Oncology, 2022, 18, 2857-2864.	1.1	1
5	Sarcoma of unknown primary: myth or reality?. Journal of the Egyptian National Cancer Institute, 2022, 34, .	0.6	1
6	Chromosomal instability in cancers of unknown primary. European Journal of Cancer, 2022, 172, 323-325.	1.3	7
7	ESO-ESMO Masterclass in Clinical Oncology: Analysis and Evaluation of the Learning Self-Assessment Test. Journal of Cancer Education, 2021, 36, 556-560.	0.6	5
8	The management of patients with cancer of unknown primary in middle-income countries: an ESO-AROME survey. Future Oncology, 2021, 17, 151-157.	1.1	2
9	Melanoma of unknown primary: New perspectives for an old story. Critical Reviews in Oncology/Hematology, 2021, 158, 103208.	2.0	37
10	Immuno-oncology: a narrative review of gastrointestinal and hepatic toxicities. Annals of Translational Medicine, 2021, 9, 423-423.	0.7	6
11	Aberrations of DNA repair pathways in prostate cancer: a cornerstone of precision oncology. Expert Opinion on Therapeutic Targets, 2021, 25, 329-333.	1.5	39
12	Genomic correlates of response and resistance to immune checkpoint inhibitors in carcinomas of unknown primary. European Journal of Clinical Investigation, 2021, 51, e13583.	1.7	15
13	The Contribution of the European School Of Oncology Education to the Central Asian and Caucasian Regions. Journal of Cancer Education, 2021, , 1.	0.6	1
14	Live European School of Oncology e-Sessions (e-ESO). Critical Reviews in Oncology/Hematology, 2021, 163, 103301.	2.0	1
15	Educational contribution of the College of the European School of Oncology to the Latin American Oncologists. Future Oncology, 2021, 17, 2981-2987.	1.1	1
16	Eight-Year Experience of the Certificate of Competence and Advanced Studies Program Organized by the European School of Oncology. Journal of Cancer Education, 2021, , 1.	0.6	1
17	The outcome of patients with serous papillary peritoneal cancer, fallopian tube cancer, and epithelial ovarian cancer by treatment eras: 27 years data from the SEER registry. Cancer Epidemiology, 2021, 75, 102045.	0.8	35
18	Cancer of unknown primary: Incidence rates, risk factors and survival among adolescents and young adults. International Journal of Cancer, 2020, 146, 1490-1498.	2.3	19

#	ARTICLE	IF	CITATIONS
19	Changing the education paradigm in oncology: ESO masterclass, 17 years of continuous success. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 146, 102798.	2.0	9
20	Veliparib in ovarian cancer: a new synthetically lethal therapeutic approach. <i>Investigational New Drugs</i> , 2020, 38, 181-193.	1.2	70
21	Synovial Sarcoma: A Complex Disease with Multifaceted Signaling and Epigenetic Landscapes. <i>Current Oncology Reports</i> , 2020, 22, 124.	1.8	8
22	The impact of the European School of Oncology masterclass in clinical oncology on self-professional development. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 151, 102976.	2.0	5
23	The diagnostic challenges of patients with carcinoma of unknown primary. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 775-783.	1.1	12
24	What can we learn from cancer of unknown primary in canine oncology?. <i>Journal of Advanced Research</i> , 2020, 24, 495-500.	4.4	3
25	Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond. <i>Drugs in R and D</i> , 2020, 20, 55-73.	1.1	84
26	The clinical training centers fellowships: a European School of Oncology career development program (2013-2019). <i>Future Oncology</i> , 2020, 16, 1969-1976.	1.1	5
27	Exploring the biological hallmarks of cancer of unknown primary: where do we stand today?. <i>British Journal of Cancer</i> , 2020, 122, 1124-1132.	2.9	41
28	New rising entities in cancer of unknown primary: Is there a real therapeutic benefit?. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 147, 102882.	2.0	42
29	The role of site-specific therapy for cancers of unknown of primary: A meta-analysis. <i>European Journal of Cancer</i> , 2020, 127, 118-122.	1.3	24
30	Progress in refining the clinical management of cancer of unknown primary in the molecular era. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 541-554.	12.5	62
31	Clinical Case Presentation and Discussion During ESO-ESMO Masterclass: a 10-Year Interactive Educational Experience. <i>Journal of Cancer Education</i> , 2020, 36, 1124-1128.	0.6	5
32	Narrative review on serous primary peritoneal carcinoma of unknown primary site: four questions to be answered. <i>Annals of Translational Medicine</i> , 2020, 8, 1709-1709.	0.7	7
33	Ovarian cancer: state of the art and perspectives of clinical research. <i>Annals of Translational Medicine</i> , 2020, 8, 1702-1702.	0.7	2
34	Development of new poly(ADP-ribose) polymerase (PARP) inhibitors in ovarian cancer: Quo Vadis?. <i>Annals of Translational Medicine</i> , 2020, 8, 1706-1706.	0.7	17
35	Wise Management of Ovarian Cancer: On the Cutting Edge. <i>Journal of Personalized Medicine</i> , 2020, 10, 41.	1.1	51
36	Advances in the management of brain metastases from cancer of unknown primary. <i>Future Oncology</i> , 2019, 15, 2759-2768.	1.1	4

#	ARTICLE	IF	CITATIONS
37	The interaction of immune checkpoint inhibitor plus chemotherapy in non-small-cell lung cancer: subadditivity, additivity or synergism?. <i>Immunotherapy</i> , 2019, 11, 913-920.	1.0	13
38	Combined Strategies with Poly (ADP-Ribose) Polymerase (PARP) Inhibitors for the Treatment of Ovarian Cancer: A Literature Review. <i>Diagnostics</i> , 2019, 9, 87.	1.3	94
39	Comprehensive management of HPV-related squamous cell carcinoma of the head and neck of unknown primary. <i>Head and Neck</i> , 2019, 41, 3700-3711.	0.9	40
40	The currently declining incidence of cancer of unknown primary. <i>Cancer Epidemiology</i> , 2019, 61, 139-141.	0.8	71
41	Comparison of second-line treatments of recurrent and/or metastatic squamous cell carcinoma of the head and neck. <i>Future Oncology</i> , 2019, 15, 909-923.	1.1	10
42	Familial cancer of unknown primary. <i>International Journal of Clinical Oncology</i> , 2019, 24, 1328-1331.	1.0	11
43	PARP Inhibitors in Ovarian Cancer: The Route to "elthaca". <i>Diagnostics</i> , 2019, 9, 55.	1.3	52
44	A new entity of abdominal squamous cell carcinoma of unknown primary. <i>European Journal of Clinical Investigation</i> , 2019, 49, e13111.	1.7	14
45	The Developing Story of Predictive Biomarkers in Colorectal Cancer. <i>Journal of Personalized Medicine</i> , 2019, 9, 12.	1.1	111
46	Paraneoplastic syndromes in cancers of unknown primary: An unknown field for oncologists. <i>Bulletin Du Cancer</i> , 2019, 106, 590-603.	0.6	9
47	A review on pregnancy complicated by ovarian epithelial and non-epithelial malignant tumors: Diagnostic and therapeutic perspectives. <i>Journal of Advanced Research</i> , 2018, 12, 1-9.	4.4	37
48	The current evidence for a biomarker-based approach in cancer of unknown primary. <i>Cancer Treatment Reviews</i> , 2018, 67, 21-28.	3.4	30
49	Extranodal diffuse large B-cell lymphomas: A retrospective case series and review of the literature. <i>Hematology Reports</i> , 2018, 10, 7070.	0.3	14
50	Liquid biopsy: a new diagnostic, predictive and prognostic window in cancers of unknown primary. <i>European Journal of Cancer</i> , 2018, 105, 28-32.	1.3	19
51	A comprehensive review of the role of immune checkpoint inhibitors in brain metastasis of renal cell carcinoma origin. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 130, 60-69.	2.0	20
52	Depression in cancer: The many biobehavioral pathways driving tumor progression. <i>Cancer Treatment Reviews</i> , 2017, 52, 58-70.	3.4	204
53	Testicular Signet-Ring Cell Metastasis from a Carcinoma of Unknown Primary Site: A Case Report and Literature Review. <i>Case Reports in Oncological Medicine</i> , 2016, 2016, 1-5.	0.2	1
54	The ESMO/ASCO Global Curriculum and the evolution of medical oncology training in Europe. <i>ESMO Open</i> , 2016, 1, e000004.	2.0	12

#	ARTICLE	IF	CITATIONS
55	ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016. ESMO Open, 2016, 1, e000097.	2.0	82
56	Lung cancer during pregnancy: A narrative review. Journal of Advanced Research, 2016, 7, 571-574.	4.4	35
57	Management of patients with recurrent/advanced cervical cancer beyond first line platinum regimens: Where do we stand? A literature review. Critical Reviews in Oncology/Hematology, 2016, 108, 164-174.	2.0	134
58	Age-Dependent Metastatic Spread and Survival: Cancer of Unknown Primary as a Model. Scientific Reports, 2016, 6, 23725.	1.6	14
59	Aromatase inhibitors induced autoimmune disorders in patients with breast cancer: A review. Journal of Advanced Research, 2016, 7, 719-726.	4.4	26
60	Bone and soft tissue sarcomas during pregnancy: A narrative review of the literature. Journal of Advanced Research, 2016, 7, 581-587.	4.4	17
61	A mini review on pregnant mothers with cancer: A paradoxical coexistence. Journal of Advanced Research, 2016, 7, 559-563.	4.4	13
62	Sense of Coherence and Defense Style Predict Sleep Difficulties in Early Non-metastatic Colorectal Cancer. Digestive Diseases and Sciences, 2016, 61, 273-282.	1.1	9
63	Cancer specific risk in multiple sclerosis patients. Critical Reviews in Oncology/Hematology, 2016, 98, 29-34.	2.0	21
64	Prognostic significance of <scp>WNT</scp> and hedgehog pathway activation markers in cancer of unknown primary. European Journal of Clinical Investigation, 2015, 45, 1145-1152.	1.7	4
65	Neuroendocrine Cell Carcinoma of Unknown Primary Arising in Long Standing History of Multiple Sclerosis. Case Reports in Oncological Medicine, 2015, 2015, 1-4.	0.2	1
66	Neuroendocrine Merkel cell nodal carcinoma of unknown primary site: Management and outcomes of a rare entity. Critical Reviews in Oncology/Hematology, 2015, 94, 116-121.	2.0	23
67	Gastrointestinal stromal tumors during pregnancy: a systematic review of an uncommon but treatable malignancy. Clinical and Translational Oncology, 2015, 17, 757-762.	1.2	7
68	Cancer of Unknown Primary origin in the genomic era: Elucidating the dark box of cancer. Cancer Treatment Reviews, 2015, 41, 598-604.	3.4	46
69	The role of human papilloma virus and p16 in occult primary of the head and neck: A comprehensive review of the literature. Oral Oncology, 2015, 51, 119-123.	0.8	22
70	A mini review on cancer of unknown primary site: A clinical puzzle for the oncologists. Journal of Advanced Research, 2015, 6, 375-382.	4.4	93
71	An unusual presentation of a patient with advanced prostate cancer, massive ascites and peritoneal metastasis: Case report and literature review. Journal of Advanced Research, 2015, 6, 517-521.	4.4	27
72	Development of a low grade lymphoma in the mastoid bone in a patient with atypical Coganâ€™s syndrome: A case report. Journal of Advanced Research, 2015, 6, 523-527.	4.4	3

#	ARTICLE	IF	CITATIONS
73	Cancer of unknown primary during pregnancy: an exceptionally rare coexistence. <i>Anticancer Research</i> , 2015, 35, 575-9.	0.5	4
74	A patient with neuroendocrine carcinoma of the urinary bladder and paraneoplastic degenerative parencephalitis: A case report and review of the literature. <i>Cancer Treatment Communications</i> , 2014, 2, 8-11.	0.4	2
75	Renal cell carcinoma in pregnancy: a rare coexistence. <i>Clinical and Translational Oncology</i> , 2014, 16, 122-127.	1.2	80
76	Major depressive disorder in breast cancer: A critical systematic review of pharmacological and psychotherapeutic clinical trials. <i>Cancer Treatment Reviews</i> , 2014, 40, 349-355.	3.4	40
77	Psychosocial predictors of health outcomes in colorectal cancer: A comprehensive review. <i>Cancer Treatment Reviews</i> , 2014, 40, 800-809.	3.4	45
78	Relapsing Episodes of Loss of Consciousness in a Patient With Hepatocellular Carcinoma. <i>World Journal of Oncology</i> , 2014, 5, 214-219.	0.6	4
79	Cancer diagnosis in a cohort of patients with Sjogren's syndrome and rheumatoid arthritis: a single-center experience and review of the literature. <i>Anticancer Research</i> , 2014, 34, 6669-76.	0.5	11
80	Psychiatric manifestations, personality traits and health-related quality of life in cancer of unknown primary site. <i>Psycho-Oncology</i> , 2013, 22, 2009-2015.	1.0	35
81	Prognostication in cancer of unknown primary (CUP): Development of a prognostic algorithm in 311 cases and review of the literature. <i>Cancer Treatment Reviews</i> , 2013, 39, 701-708.	3.4	47
82	Global microRNA profiling in favorable prognosis subgroups of cancer of unknown primary (CUP) demonstrates no significant expression differences with metastases of matched known primary tumors. <i>Clinical and Experimental Metastasis</i> , 2013, 30, 431-439.	1.7	23
83	Exploring the biology of cancer of unknown primary: breakthroughs and drawbacks. <i>European Journal of Clinical Investigation</i> , 2013, 43, 491-500.	1.7	50
84	Cancer of Unknown Primary Site: The Pathologist's Point of View. <i>The Journal of Oncopathology</i> , 2013, 1, 47-54.	0.1	1
85	Prognostic Significance of ESR1 Gene Amplification, mRNA/Protein Expression and Functional Profiles in High-Risk Early Breast Cancer: A Translational Study of the Hellenic Cooperative Oncology Group (HeCOG). <i>PLoS ONE</i> , 2013, 8, e70634.	1.1	15
86	Intracellular signalling via the AKT axis and downstream effectors is active and prognostically significant in cancer of unknown primary (CUP): a study of 100 CUP cases. <i>Annals of Oncology</i> , 2012, 23, 2725-2730.	0.6	16
87	Cancer of unknown primary site. <i>Lancet, The</i> , 2012, 379, 1428-1435.	6.3	468
88	Does psychological distress vary between younger and older adults in health and disease?. <i>Journal of Psychosomatic Research</i> , 2012, 72, 120-128.	1.2	22
89	Long-term survivors among patients with cancer of unknown primary. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 84, 85-92.	2.0	19
90	Profiling clinical cancer research across the Atlantic: A review of research and its characteristics presented at ASCO and ESMO Congresses during the last decade. <i>Cancer Treatment Reviews</i> , 2012, 38, 560-565.	3.4	1

#	ARTICLE	IF	CITATIONS
91	Prognosis of pregnancy-associated breast cancer: A meta-analysis of 30 studies. <i>Cancer Treatment Reviews</i> , 2012, 38, 834-842.	3.4	199
92	Profiling immunohistochemical expression of NOTCH1, JAGGED1, cMET, and phospho-MAPK in 100 carcinomas of unknown primary. <i>Clinical and Experimental Metastasis</i> , 2012, 29, 603-614.	1.7	15
93	Improved Outcome of High-Risk Early HER2 Positive Breast Cancer With High CXCL13-CXCR5 Messenger RNA Expression. <i>Clinical Breast Cancer</i> , 2012, 12, 183-193.	1.1	49
94	Cancer prevalence and mortality in centenarians: A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 83, 145-152.	2.0	69
95	Undergraduate training in oncology: An ESO continuing challenge for medical students. <i>Surgical Oncology</i> , 2012, 21, 15-21.	0.8	34
96	Systemic treatment-induced gastrointestinal toxicity: incidence, clinical presentation and management. <i>Annals of Gastroenterology</i> , 2012, 25, 106-118.	0.4	119
97	Immunohistochemical study of the epithelial-mesenchymal transition phenotype in cancer of unknown primary: incidence, correlations and prognostic utility. <i>Anticancer Research</i> , 2012, 32, 1273-81.	0.5	25
98	Cancer of unknown primary patients with midline nodal distribution: Midway between poor and favourable prognosis?. <i>Cancer Treatment Reviews</i> , 2011, 37, 120-126.	3.4	25
99	Neuroendocrine carcinoma of unknown primary: A systematic review of the literature and a comparative study with other neuroendocrine tumors. <i>Cancer Treatment Reviews</i> , 2011, 37, 358-365.	3.4	58
100	Personality variables as predictors of early non-metastatic colorectal cancer patients' psychological distress and health-related quality of life: A one-year prospective study. <i>Journal of Psychosomatic Research</i> , 2011, 70, 411-421.	1.2	63
101	Cancer and pregnancy: what should we know about the management with systemic treatment of pregnant women with cancer?. <i>European Journal of Cancer</i> , 2011, 47, S348-S352.	1.3	17
102	Prognostic utility of β -tubulin isotype III and correlations with other molecular and clinicopathological variables in patients with early breast cancer: a translational Hellenic Cooperative Oncology Group (HeCOG) study. <i>Breast Cancer Research and Treatment</i> , 2011, 127, 179-193.	1.1	36
103	Euro-Arab School of Oncology: an Educational Collaborative Activity of the European School of Oncology with the Arab World. <i>Journal of Cancer Education</i> , 2011, 26, 129-133.	0.6	2
104	Phase I trial of weekly irinotecan and paclitaxel combined with carboplatin in patients with advanced cancer: a Hellenic Cooperative Oncology Group Study. <i>Anti-Cancer Drugs</i> , 2010, 21, 785-789.	0.7	4
105	Axillary nodal metastases from carcinoma of unknown primary (CUPAx): a systematic review of published evidence. <i>Breast Cancer Research and Treatment</i> , 2010, 119, 1-11.	1.1	93
106	Serous papillary peritoneal carcinoma: Unknown primary tumour, ovarian cancer counterpart or a distinct entity? A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2010, 75, 27-42.	2.0	79
107	Probing the unknown in cancer of unknown primary: which way is the right way?. <i>Annals of Oncology</i> , 2010, 21, 1143-1144.	0.6	4
108	Lung cancer in the pregnant woman: To treat or not to treat, that is the question. <i>Lung Cancer</i> , 2010, 67, 251-256.	0.9	56

#	ARTICLE	IF	CITATIONS
109	High levels of topoisomerase III α protein expression in diffuse large B-cell lymphoma are associated with high proliferation, germinal center immunophenotype, and response to treatment. <i>Leukemia and Lymphoma</i> , 2010, 51, 1260-1268.	0.6	14
110	Treatment of the pregnant mother with cancer: A systematic review on the use of cytotoxic, endocrine, targeted agents and immunotherapy during pregnancy. Part I: Solid tumors. <i>Cancer Treatment Reviews</i> , 2010, 36, 101-109.	3.4	117
111	Treatment of the pregnant mother with cancer: A systematic review on the use of cytotoxic, endocrine, targeted agents and immunotherapy during pregnancy. Part II: Hematological tumors. <i>Cancer Treatment Reviews</i> , 2010, 36, 110-121.	3.4	141
112	Cancer of Unknown Primary: What Kind of Chemotherapy? What Kind of Disease?. <i>Oncology Research and Treatment</i> , 2009, 32, 159-160.	0.8	3
113	Dose-Ranging Study of Metronomic Oral Vinorelbine in Patients with Advanced Refractory Cancer. <i>Clinical Cancer Research</i> , 2009, 15, 6454-6461.	3.2	97
114	Successful publishing: How to get your paper accepted. <i>Surgical Oncology</i> , 2009, 18, 350-356.	0.8	28
115	Treatment for Patients With Unknown Primary Carcinoma and Unfavorable Prognostic Factors. <i>Seminars in Oncology</i> , 2009, 36, 65-74.	0.8	87
116	Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial. <i>Breast Cancer Research and Treatment</i> , 2009, 116, 131-143.	1.1	61
117	Donor-derived breast cancer in a bone marrow transplantation recipient. <i>Breast Cancer Research and Treatment</i> , 2009, 113, 211-213.	1.1	17
118	Somatization is associated with physical health-related quality of life independent of anxiety and depression in cancer, glaucoma and rheumatological disorders. <i>Quality of Life Research</i> , 2009, 18, 1029-1042.	1.5	30
119	Screening practice and misplaced priorities. <i>Clinical and Translational Oncology</i> , 2009, 11, 228-236.	1.2	3
120	Cervical lymph node metastases of squamous cell carcinoma from an unknown primary site: a favourable prognosis subset of patients with CUP. <i>Clinical and Translational Oncology</i> , 2009, 11, 340-348.	1.2	53
121	Presentation, Management and Outcome of 32 Patients with Pregnancy-Associated Breast Cancer: A Matched Controlled Study. <i>Breast Journal</i> , 2009, 15, 461-467.	0.4	79
122	Carcinoma of unknown primary (CUP). <i>Critical Reviews in Oncology/Hematology</i> , 2009, 69, 271-278.	2.0	210
123	Molecular assignment of tissue of origin in cancer of unknown primary may not predict response to therapy or outcome: A systematic literature review. <i>Cancer Treatment Reviews</i> , 2009, 35, 221-227.	3.4	80
124	Comparative survival with diverse chemotherapy regimens for cancer of unknown primary site: Multiple-treatments meta-analysis. <i>Cancer Treatment Reviews</i> , 2009, 35, 570-573.	3.4	109
125	Evidence-based medicine: Development and implementation of guidelines in oncology. <i>European Journal of Cancer</i> , 2009, 45, 468-470.	1.3	8
126	Palliative chemotherapy in elderly patients with common metastatic malignancies: A Hellenic Cooperative Oncology Group registry analysis of management, outcome and clinical benefit predictors. <i>Critical Reviews in Oncology/Hematology</i> , 2008, 66, 237-247.	2.0	37

#	ARTICLE	IF	CITATIONS
127	Integrating trastuzumab in the neoadjuvant treatment of primary breast cancer: Accumulating evidence of efficacy, synergy and safety. <i>Critical Reviews in Oncology/Hematology</i> , 2008, 66, 31-41.	2.0	32
128	Liver metastases from cancer of unknown primary (CUPL): A retrospective analysis of presentation, management and prognosis in 49 patients and systematic review of the literature. <i>Cancer Treatment Reviews</i> , 2008, 34, 693-700.	3.4	56
129	Gastrointestinal, Urologic and Lung Malignancies During Pregnancy. , 2008, 178, 137-164.		14
130	Personality Factors Associated With Psychological Distress in Testicular Cancer Survivors. <i>Journal of Personality Assessment</i> , 2008, 90, 348-355.	1.3	13
131	Metastatic Involvement of Placenta and Foetus in Pregnant Women with Cancer. , 2008, 178, 183-194.		51
132	Forty years experience of treating cancer of unknown primary. <i>Acta OncolÃ³gica</i> , 2007, 46, 592-601.	0.8	68
133	Cancer of Unknown Primary Site: Missing Primary or Missing Biology?. <i>Oncologist</i> , 2007, 12, 418-425.	1.9	127
134	Response: Re: Survival With Aromatase Inhibitors and Inactivators Versus Standard Hormonal Therapy in Advanced Breast Cancer: Meta-analysis. <i>Journal of the National Cancer Institute</i> , 2007, 99, 176-177.	3.0	1
135	Switching benchmarks in cancer of unknown primary: From autopsy to microarray. <i>European Journal of Cancer</i> , 2007, 43, 2026-2036.	1.3	229
136	Effects of different chemotherapy regimens on survival for advanced cervical cancer: Systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2007, 33, 24-38.	3.4	35
137	Editorial: Adolescent oncology. <i>Cancer Treatment Reviews</i> , 2007, 33, 595-596.	3.4	3
138	Late toxicity in survivors from adolescent cancers. <i>Cancer Treatment Reviews</i> , 2007, 33, 656-663.	3.4	15
139	Survival and disease-progression benefits with treatment regimens for advanced colorectal cancer: a meta-analysis. <i>Lancet Oncology</i> , The, 2007, 8, 898-911.	5.1	149
140	Global profiling of EGFR gene mutation, amplification, regulation and tissue protein expression in unknown primary carcinomas: to target or not to target?. <i>Clinical and Experimental Metastasis</i> , 2007, 24, 79-86.	1.7	26
141	Survivin and glycodeilin transcriptional activity in node-positive early breast cancer: mRNA expression of two key regulators of cell survival. <i>Breast Cancer Research and Treatment</i> , 2006, 100, 161-167.	1.1	14
142	Treatment of colorectal cancer in the elderly: A review of the literature. <i>Cancer Treatment Reviews</i> , 2006, 32, 1-8.	3.4	64
143	Cancer treatment reviews welcomes submission of the Cochrane Reviews. <i>Cancer Treatment Reviews</i> , 2006, 32, 243-244.	3.4	1
144	Perspectives for targeted therapies in cancer of unknown primary site. <i>Cancer Treatment Reviews</i> , 2006, 32, 637-644.	3.4	18

#	ARTICLE	IF	CITATIONS
145	Cancer and pregnancy: Poena magna, not anymore. <i>European Journal of Cancer</i> , 2006, 42, 126-140.	1.3	229
146	Feasibility study and pharmacokinetics of low-dose paclitaxel in cancer patients with severe hepatic dysfunction. <i>Anti-Cancer Drugs</i> , 2006, 17, 1219-1222.	0.7	6
147	Metastatic breast cancer with liver metastases: a registry analysis of clinicopathologic, management and outcome characteristics of 500 women. <i>Breast Cancer Research and Treatment</i> , 2006, 97, 237-244.	1.1	101
148	Elderly patients with squamous lung carcinoma: faring better or worse?. <i>Supportive Care in Cancer</i> , 2006, 14, 867-870.	1.0	1
149	«Juvenile» oncology - a missing subspecialty. The experience of a reference cancer centre. <i>Clinical and Translational Oncology</i> , 2006, 8, 444-449.	1.2	1
150	Survival With Aromatase Inhibitors and Inactivators Versus Standard Hormonal Therapy in Advanced Breast Cancer: Meta-analysis. <i>Journal of the National Cancer Institute</i> , 2006, 98, 1285-1291.	3.0	242
151	Survival Benefits With Diverse Chemotherapy Regimens for Ovarian Cancer: Meta-analysis of Multiple Treatments. <i>Journal of the National Cancer Institute</i> , 2006, 98, 1655-1663.	3.0	159
152	Old habits die hard: chest radiography for screening purposes in primary care. <i>American Journal of Managed Care</i> , 2006, 12, 650-6.	0.8	5
153	Cancer of unknown primary (CUP). <i>Critical Reviews in Oncology/Hematology</i> , 2005, 54, 243-250.	2.0	147
154	Prognostic Factors in Patients with Colorectal Cancer Receiving Adjuvant Chemotherapy or Chemoradiotherapy: A Pooled Analysis of Two Randomized Studies. <i>International Journal of Gastrointestinal Cancer</i> , 2005, 36, 029-038.	0.4	5
155	Paclitaxel, Cisplatin, Leucovorin, and Continuous Infusion Fluorouracil Followed by Concomitant Chemoradiotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck: A Hellenic Cooperative Oncology Group Phase II Study. <i>Medical Oncology</i> , 2005, 22, 269-280.	1.2	7
156	Angiogenesis in cancer of unknown primary: clinicopathological study of CD34, VEGF and TSP-1. <i>BMC Cancer</i> , 2005, 5, 25.	1.1	58
157	Matrix metalloproteinases in carcinoma of unknown primary. <i>Cancer</i> , 2005, 104, 2282-2287.	2.0	32
158	Pharmacokinetics of imatinib mesylate in end stage renal disease. A case study. <i>Cancer Chemotherapy and Pharmacology</i> , 2005, 56, 358-360.	1.1	38
159	Chemotherapy for patients with two favourable subsets of unknown primary carcinoma: Active, but how effective?. <i>Acta Oncologica</i> , 2005, 44, 155-160.	0.8	25
160	Neoadjuvant Versus Adjuvant Systemic Treatment in Breast Cancer: A Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2005, 97, 188-194.	3.0	1,018
161	Oxaliplatin (Eloxatin®, [©]) Plus Irinotecan Combination Chemotherapy Found Effective in Refractory Metastatic Insular Thyroid Carcinoma. <i>Thyroid</i> , 2005, 15, 614-617.	2.4	3
162	Brain metastasis of unknown primary: A diagnostic and therapeutic dilemma. <i>Cancer Treatment Reviews</i> , 2005, 31, 247-255.	3.4	55

#	ARTICLE	IF	CITATIONS
163	The pregnant mother with breast cancer: Diagnostic and therapeutic management. <i>Cancer Treatment Reviews</i> , 2005, 31, 439-447.	3.4	82
164	Inflammatory prostate cancer: An underestimated paraneoplastic clinical manifestation. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2005, 23, 318-322.	0.8	14
165	Management of leptomeningeal malignancy. <i>Expert Opinion on Pharmacotherapy</i> , 2005, 6, 1115-1125.	0.9	53
166	Gemcitabine plus pegylated liposomal doxorubicin in patients with advanced epithelial ovarian cancer resistant/refractory to platinum and/or taxanes. A HeCOG phase II study. <i>Anticancer Research</i> , 2005, 25, 3103-8.	0.5	18
167	Interaction pharmacokinetics of pegylated liposomal doxorubicin (Caelyx) on coadministration with paclitaxel or docetaxel. <i>Cancer Chemotherapy and Pharmacology</i> , 2004, 53, 452-457.	1.1	46
168	Metastatic breast carcinoma confined to bone. <i>Cancer</i> , 2004, 101, 1524-1528.	2.0	61
169	Intensified Bimonthly Cisplatin With Bolus 5-Fluorouracil, Continuous 5-Fluorouracil and High-Dose Leucovorin (LV5FU2) in Patients With Advanced Gastrointestinal Carcinomas. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2004, 27, 465-471.	0.6	2
170	Biweekly Administration of Low-Dose Docetaxel in Hormone-Resistant Prostate Cancer: Pilot Study of an Effective Subtoxic Therapy. <i>Clinical Prostate Cancer</i> , 2003, 2, 46-49.	2.1	13
171	Pharmacodynamics of non-break weekly paclitaxel (Taxol) and pharmacokinetics of Cremophor-EL vehicle: results of a dose-escalation study. <i>Anti-Cancer Drugs</i> , 2002, 13, 481-489.	0.7	17
172	Dose-Dense Sequential Chemotherapy With Epirubicin and Paclitaxel Versus the Combination, as First-Line Chemotherapy, in Advanced Breast Cancer: A Randomized Study Conducted by the Hellenic Cooperative Oncology Group. <i>Journal of Clinical Oncology</i> , 2001, 19, 2232-2239.	0.8	22
173	G-CSF induces elevation of circulating CA 15-3 in breast carcinoma patients treated in an adjuvant setting. <i>Cancer</i> , 2001, 91, 909-917.	2.0	18
174	Dose-Dense Sequential Chemotherapy with Epirubicin and Paclitaxel in Advanced Breast Cancer. <i>Cancer Investigation</i> , 2001, 19, 137-144.	0.6	4
175	Noncardiogenic Pulmonary Edema: An Unusual and Serious Complication of Anticancer Therapy. <i>Oncologist</i> , 2001, 6, 153-161.	1.9	86
176	Carboplatin Plus Paclitaxel in Unknown Primary Carcinoma: A Phase II Hellenic Cooperative Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2000, 18, 3101-3107.	0.8	182
177	Carzelesin phase II study in advanced breast, ovarian, colorectal, gastric, head and neck cancer, non-Hodgkin's lymphoma and malignant melanoma: a study of the EORTC early clinical studies group (ECSG). <i>Cancer Chemotherapy and Pharmacology</i> , 2000, 46, 167-171.	1.1	37
178	Phase I Trial of 6-Hour Infusion of Glufosfamide, a New Alkylating Agent With Potentially Enhanced Selectivity for Tumors That Overexpress Transmembrane Glucose Transporters: A Study of the European Organization for Research and Treatment of Cancer Early Clinical Studies Group. <i>Journal of Clinical Oncology</i> , 2000, 18, 3535-3544.	0.8	54
179	Chemotherapy-Induced Noncardiogenic Pulmonary Edema Related to Gemcitabine plus Docetaxel Combination with Granulocyte Colony-Stimulating Factor Support. <i>Respiration</i> , 2000, 67, 680-683.	1.2	28
180	Docetaxel and Gemcitabine in Anthracycline-Resistant Advanced Breast Cancer: A Hellenic Cooperative Oncology Group Phase II Study. <i>Cancer Investigation</i> , 2000, 18, 503-509.	0.6	57

#	ARTICLE	IF	CITATIONS
181	High-dose epirubicin and r-met-hu G-CSF (Filgrastim) in the treatment of patients with advanced breast cancer: A hellenic cooperative oncology group study. Medical and Pediatric Oncology, 1995, 24, 23-28.	1.0	8
182	Evaluation of six tumor markers in patients with carcinoma of unknown primary. Medical and Pediatric Oncology, 1994, 22, 162-167.	1.0	53
183	Is androgen substitution necessary in hypogonadal patients when they are treated with chemotherapy for malignant diseases?. Medical and Pediatric Oncology, 1989, 17, 222-226.	1.0	2